Vir Biotechnology Inc (VIR) Stock Price, Quote & News

Company Profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metap...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 906 4324

Website: www.vir.bio

Address:

1800 Owens Street, Suite 900, San Francisco, United States

Dunnieboy1 Jan. 30 at 2:38 PM

$VIR $8 looks imminent.

1 · Reply

Denmarhj Jan. 30 at 10:03 AM

$VIR Low float, quiet accumulation—could squeeze if volume picks up

0 · Reply

Dunnieboy1 Jan. 30 at 8:32 AM

$VIR Yahoo have done a article on Vir Bio. The market size for chronic hepatitis D in the leading markets is expected to grow significantly by 2034. The United States accounted for the highest chronic hepatitis D treatment market size in 7MM in 2024, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan. Over 12 million people globally are chronically infected with the hepatitis D virus, which is recognized as the most severe form of viral hepatitis.

0 · Reply

newTrader9999 Jan. 29 at 4:22 PM

$VIR when is ASCO GU presentation in Feb?

0 · Reply

Mhand Jan. 29 at 2:25 PM

$VIR No pre-market volume, may be a good sign that the shorting will be at a minimum today. Hopefully a low volume grind upward. Maybe break the $8 barrier?

0 · Reply

BillionerOfKing Jan. 29 at 11:48 AM

$VIR Current Stock Price: $7.59 Contracts to trade: $10 VIR Feb 20 2026 Call Entry: $0.05 Exit: $0.07 ROI: 50% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Dunnieboy1 Jan. 28 at 3:37 PM

$VIR showing a bit of fight & coming back up.

0 · Reply

VIR_Tical1 Jan. 28 at 3:11 PM

$VIR Good Read by EQUITY INSIDER Tue, Jan 27, 2026 at 10:50 AM In part, “Vir Biotechnology is progressing additional PRO-XTEN masked T-cell engagers in preclinical studies directed at clinically validated targets with potential applications across lung, colorectal and bladder cancers, all discovered using the Company's proprietary antibody and T-cell engager discovery platform including dAIsY, a proprietary artificial intelligence engine, and the universal PRO-XTEN masking technology.” Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Jan. 27, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary

0 · Reply

Dunnieboy1 Jan. 28 at 11:00 AM

$VIR could we get into the $8-$9 range today? We normally bounce off a new level a few times before getting above it but momentum is a powerful driver so you never know.

0 · Reply

metalcook Jan. 28 at 10:40 AM

$VIR shorts at 1y high.. something will happen soon (back to 5$ or break out soo n)

0 · Reply

Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:00 AM EST - 19 days ago

Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones

Jan 5, 2026, 4:05 PM EST - 26 days ago

Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 16, 2025, 4:05 PM EST - 6 weeks ago

Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program

Nov 19, 2025, 4:05 PM EST - 2 months ago

Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference

Nov 9, 2025, 6:07 PM EST - 2 months ago

Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile

Nov 7, 2025, 9:00 AM EST - 3 months ago

Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference

Nov 5, 2025, 9:41 PM EST - 3 months ago

Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 3 months ago

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 8:00 AM EST - 3 months ago

Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta

Oct 22, 2025, 4:05 PM EDT - 3 months ago

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 9, 2025, 4:05 PM EDT - 4 months ago

Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN® Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer

Oct 7, 2025, 8:00 AM EDT - 4 months ago

Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025

Sep 16, 2025, 1:15 PM EDT - 4 months ago

Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 25, 2025, 4:05 PM EDT - 5 months ago

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 6, 2025, 11:01 PM EDT - 6 months ago

Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 6 months ago

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 8:05 AM EDT - 6 months ago

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 31, 2025, 8:05 AM EDT - 6 months ago

Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta

Jul 24, 2025, 8:05 AM EDT - 6 months ago

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of EGFR-Targeting PRO-XTEN™ Dual-Masked T-Cell Engager VIR-5525 for the Treatment of Solid Tumors

Jul 23, 2025, 12:10 PM EDT - 6 months ago

Vir Biotechnology: Hep B And Cancer Projects March On

Jul 22, 2025, 4:05 PM EDT - 6 months ago

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025

Jun 11, 2025, 7:00 AM EDT - 8 months ago

20 stocks you should avoid — no matter how well the market does

CORT CPRX CRK CRNC DDD LUMN LYV

May 28, 2025, 4:05 PM EDT - 8 months ago

Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025

May 20, 2025, 4:05 PM EDT - 9 months ago

Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit

May 12, 2025, 4:05 PM EDT - 9 months ago

Vir Biotechnology to Participate in Bank of America Securities 2025 Healthcare Conference

May 9, 2025, 6:00 AM EDT - 9 months ago

Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study

May 8, 2025, 3:37 PM EDT - 9 months ago

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 7, 2025, 11:21 PM EDT - 9 months ago

Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 9 months ago

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 9 months ago

Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025

Apr 24, 2025, 9:30 AM EDT - 10 months ago

Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025

Mar 21, 2025, 7:10 AM EDT - 11 months ago

Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results

Mar 13, 2025, 8:05 AM EDT - 11 months ago

Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta

Feb 26, 2025, 11:22 PM EST - 1 year ago

Vir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 19, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology to Participate in TD Cowen 45th Annual Health Care Conference

Feb 12, 2025, 4:05 PM EST - 1 year ago

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

Jan 13, 2025, 6:10 PM EST - 1 year ago

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

ABBV AMGN AZN BNTX FBCG GILD GSK

Jan 10, 2025, 2:32 PM EST - 1 year ago

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why

Jan 9, 2025, 9:00 AM EST - 1 year ago

Vir Biotechnology: A Rocket Off Phase 1 Data

Jan 8, 2025, 12:28 PM EST - 1 year ago

Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why

Jan 8, 2025, 7:45 AM EST - 1 year ago

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

Dec 18, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 13, 2024, 12:57 PM EST - 1 year ago

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Dec 12, 2024, 4:05 PM EST - 1 year ago

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta

Nov 26, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs

Nov 25, 2024, 9:30 AM EST - 1 year ago

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 9:15 PM EST - 1 year ago

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Nov 18, 2024, 4:05 PM EST - 1 year ago

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Dunnieboy1 Jan. 30 at 2:38 PM

$VIR $8 looks imminent.

1 · Reply

Denmarhj Jan. 30 at 10:03 AM

$VIR Low float, quiet accumulation—could squeeze if volume picks up

0 · Reply

Dunnieboy1 Jan. 30 at 8:32 AM

0 · Reply

newTrader9999 Jan. 29 at 4:22 PM

$VIR when is ASCO GU presentation in Feb?

0 · Reply

Mhand Jan. 29 at 2:25 PM

$VIR No pre-market volume, may be a good sign that the shorting will be at a minimum today. Hopefully a low volume grind upward. Maybe break the $8 barrier?

0 · Reply

BillionerOfKing Jan. 29 at 11:48 AM

0 · Reply

Dunnieboy1 Jan. 28 at 3:37 PM

$VIR showing a bit of fight & coming back up.

0 · Reply

VIR_Tical1 Jan. 28 at 3:11 PM

0 · Reply

Dunnieboy1 Jan. 28 at 11:00 AM

$VIR could we get into the $8-$9 range today? We normally bounce off a new level a few times before getting above it but momentum is a powerful driver so you never know.

0 · Reply

metalcook Jan. 28 at 10:40 AM

$VIR shorts at 1y high.. something will happen soon (back to 5$ or break out soo n)

0 · Reply

Dunnieboy1 Jan. 27 at 9:03 PM

$VIR good day, getting spoilt 😂

0 · Reply

JFDI Jan. 27 at 3:39 PM

$VIR

1 · Reply

Dunnieboy1 Jan. 27 at 3:25 PM

$VIR our time to shine, hopefully it’s been a long time coming.

0 · Reply

Dunnieboy1 Jan. 27 at 2:36 PM

$VIR 7.73 could we test $8

0 · Reply

VIR_Tical1 Jan. 27 at 1:02 AM

📈 Deep Dive On $VIR by @optionsflowboss X Strong Buy w/17.50 https://x.com/optionsflowboss/status/2014711578713522561?s=12

1 · Reply

Dunnieboy1 Jan. 26 at 9:51 PM

$VIR no Softbank sales last week🤞

1 · Reply

Dunnieboy1 Jan. 26 at 2:40 PM

$VIR bit of a dip think we’ll recover later

0 · Reply

newTrader9999 Jan. 26 at 10:26 AM

$VIR finally almost breakeven after underwater for last 1 year

0 · Reply

Electhim Jan. 26 at 2:02 AM

$VIR Big week ahead

0 · Reply

newTrader9999 Jan. 25 at 4:00 AM

$VIR when is ASCO GU Vir presentation?

1 · Reply

peepthestamp Jan. 24 at 12:38 AM

$VIR

0 · Reply

Dunnieboy1 Jan. 23 at 9:55 PM

$VIR a great week for Vir shareholders.

0 · Reply

Market Cap	1.08B
Revenue (ttm)	74.21M
Net Income (ttm)	-521.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-703.36%
Debt to Equity Ratio	0.00

Volume	1,904,400
Avg Vol	1,916,026
Day's Range	N/A - N/A
Shares Out	139.13M
Stochastic %K	79%
Beta	1.39
Analysts	Strong Sell
Price Target	$17.11